Funded Biotechnology Startups in New York
Among the 50 most recent biotechnology rounds tied to New York, the largest disclosed amount is Definium Therapeutics’ $805M (2026-06-23), which dwarfs the…
Among the 50 most recent biotechnology rounds tied to New York, the largest disclosed amount is Definium Therapeutics’ $805M (2026-06-23), which dwarfs the rest of the disclosed figures in the table. At the other end, the smallest disclosed amount is $40K for BioVaxys (2025-04-01), creating a wide spread from seed-stage amounts up through very large checks. Most entries are labeled “Series Unknown” (25 of 50), and a smaller set specify rounds (e.g., Series A and Series B each appear multiple times; Seed appears in 4 rows, and Pre-Seed appears once).
Date-wise, the newest round is Nuvation Bio’s $250M on 2026-06-25, while the oldest shown is TG Therapeutics on 2024-08-06. Many companies are concentrated in New York, New York (including Definium Therapeutics on 2026-06-23 and several other multi-$M rounds like Metsera’s $215M on 2024-11-13 and Neurogene’s $200M on 2024-11-04), with fewer explicitly listed as “New York, United States.”
Most recent rounds
50 of 12676 more funded startups
This page shows the 50 most recent rounds (back to Aug 2024). The full 126-company history for this listing is available on a paid plan.
Unlock all 126 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
What’s the largest disclosed round here, and how extreme is it versus the rest?
Definium Therapeutics’ $805M (2026-06-23) is the only disclosed amount in this table that sits far above the rest of the range. The next-largest disclosed figures include Nuvation Bio’s $250M (2026-06-25) and Neurogene’s $200M (2024-11-04), but none approach $805M.
Are there clear clusters by time within the most recent window shown?
Yes: June 2026 alone contains several of the newest disclosed rounds, including Nuvation Bio ($250M on 2026-06-25), Definium Therapeutics ($805M on 2026-06-23), and Eyenovia ($10M on 2026-05-06) just a few weeks earlier. The table also has a second dense stretch in late 2024, with multiple rounds in November 2024 such as Metsera ($215M on 2024-11-13) and Neurogene ($200M on 2024-11-04).
How often are amounts or stages unspecified, and what does that imply for deal-size comparisons?
Stage is “Series Unknown” in 25 of 50 rows, and “undisclosed” appears as the amount in multiple entries (e.g., ARMR Sciences on 2026-06-23 and National Kidney Foundation on 2026-06-01). That means size comparisons depend heavily on the disclosed subset, making the $805M outlier (Definium Therapeutics, 2026-06-23) especially impactful among the known figures.
Which rounds look like true outliers in the disclosed range?
Definium Therapeutics’ $805M (2026-06-23) is the standout high outlier. On the low end, BioVaxys’ $40K (2025-04-01) is the smallest disclosed amount, far below other small reported checks like GenKardia’s $250K (2025-05-07) and Reme-D’s $500K (2026-04-02).
Is New York City (New York, New York) over-represented versus broader New York listings?
A large share of the largest disclosed rounds are explicitly located in “New York, New York, United States,” including Definium Therapeutics ($805M on 2026-06-23), Renaissance Philanthropy ($533M on 2026-05-06), and Metsera ($215M on 2024-11-13). Several others are labeled more broadly “New York, United States” (for example Nuvation Bio at $250M on 2026-06-25 and Waypoint Bio at $20M on 2026-05-27), but the highest-dollar entries skew toward the city-specific label.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.